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Abstract
Background:  Various ophthalmic viscosurgical devices (OVD) are used to perform
phacoemulsification and other intraocular surgeries. We performed a study to compare the efficacy
and safety of three ophthalmic viscosurgical devices that are routinely used in phacoemulsification.
Methods: Fifty-six patients of immature senile cataract with hard nucleus (grade 3 and 4) who
underwent phacoemulsification were included. Depending upon the type of OVD, patients were
randomly allocated into three groups; group 1 (n = 19), Viscoat® was used; group 2 (n = 19), Healon
GV® was used; group 3 (n = 18), Healon 5® was used. Parameters evaluated were uncorrected and
best corrected visual acuity, specular microscopy, intraocular pressure and pachymetry both
preoperatively and postoperatively on day 1, 1 week, 1 month and 3 months and development of
any complication both intraoperative and postoperative were also noted.
Results: The mean increase in central corneal thickness was 15.17% (group 1); 17.26% (group 2)
and 16.21% (group 3) on first postoperative day and was comparable in the three groups. The
density of endothelial cells decreased postoperatively (day 1) by 12.54% (group 1), 13.76% (group
2) and 13.06% (group 3) and was comparable. The mean preoperative intraocular pressure in
groups 1, 2 and 3 were 13.3 ± 2.0, 14.0 ± 2.2 and 13.2 ± 3.2 mmHg respectively, which changed to
16.0 ± 4.7, 12.2 ± 4.7 and 12.3 ± 4.8 respectively on first postoperative day and the change in
intraocular pressure was significantly higher in group 1 (1 vs 2 & 1 vs 3; p = 0.02; oneway ANOVA).
Conclusion: Viscoat®, Healon GV® and Healon 5® give comparable results in terms of efficacy and
safety in performing phacoemulsification.
Background
Ophthalmic Viscosurgical Devices (OVDs) have played a
key role in the success of phacoemulsification. An ideal
OVD is one which is able to maintain the anterior
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chamber during the procedure particularly capsulorhexis,
phaco probe entry and initial phacoemulsification and
during intraocular lens implantation, maintain mydriasis
and media clarity, protect the endothelium from phaco
energy and also prevent postoperative rise in intraocular
pressure. Although, till date, no OVD can be considered
ideal, corneal endothelial cell loss during cataract surgery
has been minimized by the use of viscoelastic substances
[1,2].
However, the incidence of variable degree of endothelial
decompensation in patients after cataract surgery remains
around 17% [3,4]. Hence, there is always the search of an
ophthalmic viscosurgical device which is ideal and that
can minimize damage to corneal endothelium and other
intraoperative complications. Over the past few years, a
partial success in this area has led to a decrease in the inci-
dence of bullous keratopathy following cataract surgery
requiring penetrating keratoplasty [5,6]. In this study, we
compared the efficacy and safety of three ophthalmic vis-
cosurgical devices namely, Viscoat® (Sodium chondroitin
sulfate 4.0% & sodium hyaluronate 3.0%), Healon GV®
(Sodium hyaluronate 1.4%) and Healon 5®  (Sodium
hyaluronate 2.3%) in hard nucleus (grade 3 and 4).
Methods
A randomized clinical trial was performed which com-
prised of 56 consecutive patients of immature senile cata-
ract with hard nucleus, who attended ophthalmic out
patient department at the Rajendra Prasad Centre for
Ophthalmic Sciences, All India Institute of Medical Sci-
ences, New Delhi, India. All patients were informed and a
written consent was obtained from them to participate in
the study.
Only those patients were included in the study, who were
more than 40 years of age, had senile cataract, nucleus
hardness of grade 3/4, not having any evidence of sublux-
ation or pseudoexfoliation and not having any other asso-
ciated ocular pathology. Patients with preoperative
diagnosed glaucoma and/or IOP greater then 20 mmHg
preoperatively were excluded from the study. Other exclu-
sion criteria were intraoperative events like manual dilata-
tion of pupil, posterior capsular rent and placement of
IOL in the sulcus.
Pre-operative evaluation of the patients included the
measurement of uncorrected and best corrected visual
acuity (UCVA and BCVA respectively), an examination of
the anterior segment of the eye under slit lamp biomicro-
scope, central corneal thickness and fundus evaluation
through a dilated pupil. Intraocular pressure was recorded
pre-operatively with a non-contact tonometer Topcon CT
– 80 (Topcon America Corporation, Paramus, NJ) in all
the patients. Keratometry was performed using Bausch
and Lomb keratometer, while the axial length was meas-
ured using an A scan biometer (Appasamy associates,
Chennai). Anterior chamber depth was recorded by
Sonomed 5500 Digital A/B Scan (Latham and Phillips
Ophthalmic Products Inc., Grove City, Ohio). The power
of the intraocular lens was calculated in all the patients
using SRK (Sanders, Retzlaff, Kraff) formula. History of
any systemic illness was excluded and blood pressure was
measured on admission.
Grading (0 to 4+) of the nuclear sclerosis (a combination
of opalescence and yellowing) was performed on slit lamp
biomicroscope. Corneal thickness was measured using
Sonomed ultrasonic pachymeter (Micropach Model
200P; Latham and Phillips Ophthalmic Products Inc.,
Grove City, Ohio). Endothelial cell counts were per-
formed with Topcon sp-2000P noncontact specular
microscope (Topcon America Corporation, Paramus, NJ).
Randomization was done pre-operatively by the statistical
random table. Surgery was performed by a single surgeon
(RBV) and the operating surgeon was told on the opera-
tion table to use single viscosurgical device allocated for
the patient for the entire procedure as per the randomiza-
tion. Those examiners (NS, JST) who performed postoper-
ative follow up and examination were masked and
unaware about the type of viscoelastic used in a particular
case.
Surgical technique
Surgeries were performed under topical anesthesia
(proparacaine 0.5%). Pupillary dilatation was achieved by
a combination of topical 0.5% tropicacyl and 5% phe-
nylephrine. A 3.2 mm clear corneal tunnel was created
either superiorly or temporally depending upon the
steeper axis; side port entry was made with the help of
microvitreoretinal (MVR) blade. OVD was injected into
the anterior chamber according to the randomization,
and capsulorhexis was performed. Hydrodissection and
hydrodelineation were performed to achieve free rotation
of nucleus. Phacoemulsification was done using crater
and chop technique by Storz protégé machine (Storz Pro-
tégé, Bausch & Lomb, NY, USA) which was followed by a
thorough irrigation and aspiration of the cortical matter.
Capsular bag was inflated with viscoelastic and a single
piece acrylic foldable IOL (ACRYSOF® SA60AT; Alcon lab-
oratories, Fort Worth, TX) was implanted in all the
patients. The OVD was completely aspirated out with the
rock and roll technique. The irrigating solution and the
phaco machine were similar in all the three groups.
Postoperatively, patients were prescribed 1% Pred-
nisolone acetate and ciprofloxacin 0.3% QID each for 4
weeks and tropicamide 1% TID for 1 week.BMC Ophthalmology 2005, 5:17 http://www.biomedcentral.com/1471-2415/5/17
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The intraoperative parameters recorded were the type of
OVD, phacoemulsification time, average ultrasonic
energy used, time required to remove the viscoelastic
material, maintenance of anterior chamber depth and
total surgical time.
Postoperatively, all the parameters were recorded on day
1, 1 week, 1 month and 3 months using the same method
and instruments.
Statistical analysis
Data were recorded on a predesigned proforma and man-
aged on Excel spread sheet. For quantitative variables,
approximate normal distribution was assessed and subse-
quently mean & standard deviation (SD) was computed
as summary statistics.
Preoperative values for all the parameters were statistically
compared amongst the three groups. Group 1 (n = 19),
comprised of eyes in which Viscoat® (Sodium chondroitin
sulfate 4.0% & sodium hyaluronate 3.0%) was used;
Group 2 (n = 19) comprised of those in which Healon
GV® (Sodium hyaluronate 1.4%) was used and Group 3 (n
= 18) comprised of those in which Healon 5® (Sodium
hyaluronate 2.3%) was used. The base line values of all
the parameters were statistically similar, therefore we used
one-way analysis of variance followed by Scheffe's post
hoc ANOVA, if required, to compare the mean values at
every line point between the three groups. Analysis of co-
variance was used to compute mean and SD values at var-
ious postoperative follow up.
Repeated measures of analysis of variance were used to
determine changes from the preoperative values. To com-
pare categorical variables between the groups, Chi square
or fisher's exact test, as appropriate, was used. STATA 8.0
and SPSS version 10.0 statistical softwares were used for
data analysis. P value of <0.05 was considered as statisti-
cally significant.
Table 1: Pre operative and Post operative characteristics of the patients
Parameter Group 1 n = 19 Group 2 n = 19 Group 3 n = 18 One-way ANOVA, 
F-Value
P value
Age 69.6 ± 9.2 65.8 ± 7.8 70.8 ± 9.9 1.58 NS
ACD 2.6 ± 0.20 2.8 ± 0.37 2.59 ± 0.45 1.97 NS
UCVA
Pre-operative 0.12 ± 0.14 0.09 ± 0.13 0.11 ± 0.9 0.18 NS
Day one 0.28 ± 19a 0.39 ± 23c 0.37 + 0.27b 1.22 NS
Three month 0.51 ± 0.16c 0.61 ± 0.20c 0.61 ± 0.20c 1.51 NS
Repeated measure within group ANOVA F = 15.0
P = 0.0001
F = 28.29
P = 0.0001
F = 23.5
P = 0.0001
BCVA
Pre-operative 0.18 ± 0.11 0.17 ± 0.19 0.18 ± 0.13 0.04 NS
Day one 0.46 ± 0.23b 0.69 ± 0.26c 0.55 ± 0.31a 1.70 NS
Three month 0.69 ± 0.24c 0.88 ± 0.18c 0.79 ± 0.23c 2.73 NS
Repeated measure within group ANOVA F = 34.17
P = 0.0001
F = 43.8
P = 0.0001
F = 23.5
P = 0.0001
Corneal thickness
Pre-operative 560.7 ± 91.5 567.5 ± 44.07 576.0 ± 50.2 0.25 NS
Day one 645.8 ± 94.1c 665.5 ± 141.9b 670.6 ± 117.1b 0.32 NS
Three month 573.4 ± 73.6 586.1 ± 29.0 586.7 ± 36.0 1.50 NS
Repeated measure within group ANOVA F = 17.5
P = 0.0001
F = 11.4
P = 0.0001
F = 11.19
P = 0.0001
Endothelial cell count.
Pre-operative 2311.73 ± 288.0 2359.78 ± 383.2 2526.6 ± 305.4 2.36 NS
Day one 2021.20 ± 201.0 2035.05 ± 377.0 2196.4 ± 378.2 0.11 NS
Three month 1973.00 ± 537.0 1959.00 ± 503.0 2132.0 ± 482.0 0.82 NS
Repeated measure within group ANOVA F = 4.2
P = 0.004
F = 2.20
P = NS
F = 17.5
P = 0.0001
a: p < 0.05, b: <0.01, c: <0.001 as compared to preoperative parameter
UCVA = Uncorrected visual acuity
BCVA = Best corrected visual acuity
ANOVA = Analysis of Variance
NS = Not SignificantBMC Ophthalmology 2005, 5:17 http://www.biomedcentral.com/1471-2415/5/17
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Results
The mean age of the patient was 68.73 ± 8.96 years and 43
(76.71%) patients were male. The three groups were com-
parable preoperatively in terms of age, anterior chamber
depth, central corneal thickness and central endothelial
cell count (Table 1). The mean preoperative uncorrected
visual acuity in the three groups was 0.12 ± 0.14, 0.09 ±
0.13 and 0.11 ± 0.9 respectively, which improved to 0.51
± 0.16, 0.61 ± 0.20 and 0.61 ± 0.20 respectively at the final
follow up at 3 months. The mean preoperative best cor-
rected visual acuity in the three groups was 0.18 ± 0.11,
0.17 ± 0.19 and 0.18 ± 0.13 respectively and this
improved to 0.69 ± 0.24, 0.88 ± 0.18 and 0.79 ± 0.23
respectively at 3 months.
The total number of eyes with grade 3 nuclear sclerosis
was 8 in Group 1, 11 in Group 2 and 4 in group 3. The
eyes with grade 4 nuclear sclerosis were 11, 8 and 14 in
group 1, group 2 and group 3 respectively.
The mean phaco energy (%) utilized was higher in Group
3 in comparison to Group 2 (p < 0.03) and Group 1 (p <
0.05) (Table 2). The total operating time was longer in
Group 3 in comparison to Group 1 (p < 0.011). Time
taken for removal of viscoelastic after IOL insertion in the
capsular bag was higher in Group 1 when compared to
Group 2 and Group 3 (Table 2). The mean increase in cen-
tral corneal thickness was 15.17% in group 1; 17.26% in
group 2 and 16.21% in group 3 on the first postoperative
day and this change was comparable in the three groups
(Table 1).
Preoperative central endothelial cell density was 2311
cells/mm2 in group 1; 2359 cells/mm2 in group 2 and
2526 cells/mm2 in group 3 (Table 3). Postoperatively, the
density of endothelial cells on day 1 decreased by 290
cells/mm2 (12.54%) in group 1 [Not significant (NS)],
324 cells/mm2 (13.76%) in group 2 (NS) and 330 cells/
mm2 (13.06%) in group 3 (NS). On comparative evalua-
tion, there was no significant difference in the change in
the endothelial count between the three groups.
The mean preoperative intraocular pressure in group 1,
group 2 and group 3 were 13.3 ± 2.0, 14.0 ± 2.2 and 13.2
± 3.2 respectively. On day 1 after surgery, the mean
intraocular pressure in the three groups were 16.0 ± 4.7,
12.2 ± 4.7, and 12.3 ± 4.8 respectively. On comparative
evaluation between the three groups, the rise in intraocu-
lar pressure in was found to be slightly higher in group 1
and significant statistically (1 vs 2 & 1 vs 3: p = 0.02; one-
way ANOVA). At 1 week follow up, the mean intraocular
pressure in the three groups were 13.8 ± 4.6, 12.0 ± 4.5
and 12.2 ± 4.7 respectively and a comparative evaluation
between the groups was not significant. The mean intraoc-
ular pressure in the three groups at 3 months were 13.0 ±
3.4, 12.1 ± 3.7 and 12.3 ± 3.6 respectively (p = ns). There
was no episode of peripheral extension of the capsulor-
hexis margin in any of the eyes. There was no evidence of
any significant intraoperative or postoperative complica-
tion in any eye.
Discussion
Optimal space maintenance during different stages of the
surgical procedure is essential to minimize mechanical
damage to the intraocular structures [7]. An increasing
number of viscoelastics with different compositions and
characteristics are now available [8]. These products differ
in their space-maintaining capabilities and other
properties.
In the present study, we observed that the anterior cham-
ber was well formed in all the patients in the three groups
during the entire procedure of capsulorhexis and phaco
probe entry and initial phacoemulsification. This property
not only helps in maintaining the chamber for better
Table 2: Intra-operative oarameters
Parameter Group 1 n = 19 Group 2 n = 19 Group 3 n = 18 One-way 
ANOVA, 
F-Value
P value Post hoc 
ANOVA, 
(Scheffe's test)
Mean phaco energy (%) 0.28 ± 0.06 0.31 ± 0.06 0.38 ± 0.09 6.75 0.0024 I Vs III: p = 0.03
II Vs III: p = 0.05
Mean phaco time (min) 2.0 ± 1.0 1.8 ± 0.8 2.1 ± 0.7 0.026 -- --
Effective phaco time (sec) 33.8 ± 17.7 36.1 ± 20.4 49.5 ± 23.1 3.31 -- --
Mean total surgical time (min) 12.9 ± 3.3 15.2 ± 3.5 16.5 ± 3.6 5.06 1 Vs III: p = 0.011
OVD removal time (sec) 66.6 ± 11.2 45.1 ± 9.0 55.47 ± 6.6 26 0.0001 I Vs II: p = 0.0001
I Vs III: p = 0.003
II Vs III: p = 0.006
OVD = Ophthalmic viscosurgical device
min = minutes
sec = secondsBMC Ophthalmology 2005, 5:17 http://www.biomedcentral.com/1471-2415/5/17
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performance of the procedure but also counteracts posi-
tive vitreous pressure during the procedure.
In our study, greater number of grade 4 nucleus was seen
in group 3. Hence the mean phaco energy and total surgi-
cal time was higher in this group in comparison to group
1 and group 2. However, there was no significant increase
in central corneal thickness in the immediate postopera-
tive period and also at the end of 3 months following sur-
gery. However, pachymetry might be slightly inaccurate as
it is impossible to measure exactly the same corneal area
every time and measurements of several corneal parts (e.g.
superior, nasal, inferior, temporal and central) should
have been performed.
There was no significant difference in the change in
endothelial count in eyes among the three groups. It is
reported in literature that endothelial cell loss rate after
phacoemulsification with IOL implantation is greater in
eyes with a hard nucleus than those with a soft nucleus [9-
11]. However, statistically, all the three viscosurgical
devices were comparable in their endothelial protective
capabilities. Ravalico G et al performed a study comparing
Healon, Healon GV, Viscoat and Hymecel (2% hydroxy-
propylmethylcellulose) and reported that Healon GV and
Viscoat are comparable in their endothelial protective
property [12]. However, another study reported a superi-
ority of Viscoat over Healon GV and Healon in terms of
protection to endothelium during phacoemulsification
[13]. Holzer MP et al reported in their study that Healon
5 is superior to Healon GV and Viscoat in terms of
endothelial protective property [14].
Several techniques have been reported in the literature for
removal of the OVDs. These include: Rock and roll tech-
nique, two-compartment technique and bimanual irriga-
tion/aspiration technique [15]. Healon-5®  has been
reported to be a viscoadaptive OVD as it has different
functions at different flow rates. At lower flow rates it
behaves as a very cohesive viscoelastic like a Healon-GV®.
At higher flow rates, e.g. in chopping techniques, it begins
to fracture and behaves similar to a dispersive viscoelastic,
such as Viscoat®.
In the present study, greater time was required to remove
the viscoelastic after IOL implantation in group 1. This
suggests that Viscoat has a more retentive nature in com-
parison to Healon GV and Healon 5 which come out in
bolus and require lesser time. Again OVD removal time
was significantly higher in group 3 in comparison to
group 2. This suggests that Healon 5 has a greater disper-
sive quality than Healon GV. Postoperatively, there was
no evidence of retention of residual OVD in the anterior
chamber of any eye on slit lamp biomicroscope.
There was a significant increase in the mean intraocular
pressure in group 1 (although in the normal range) in
comparison to group 2 (p = 0.02) and 3 (p = 0.02) on day
1 of the postoperative phase. However, at subsequent fol-
low up visits, there was no significant difference in the
mean intraocular pressure among the three groups. This
transient rise in the mean intraocular pressure in group 1
suggests that although on slit lamp biomicroscopy, there
was no direct evidence of retained viscosurgical device in
the anterior chamber, there may be microscopic retention
in the trabecular meshwork that can go undetected on
routine examination. This microscopic retention can
decrease the aqueous outflow transiently and result in var-
iable increase in intraocular pressure. Subsequently, it gets
drained off and the intraocular pressure returns close to
the baseline value. A similar study comparing Healon 5
with Viscoat reported that the IOP in the early postopera-
tive period was higher in the Viscoat group than in the
Healon 5 group [16]. However, another study comparing
Healon GV, Healon 5 and Iviz (Sodium hyaluronate 1%)
concludes that although Healon 5 takes longer time for
removal, there is no significant difference in the postoper-
ative intraocular pressure [17].
Conclusion
In the present study, we conclude that the safety and effi-
cacy of the three viscosurgical devices namely Viscoat®,
Healon GV®  and Healon 5®  in performing
phacoemulsification is comparable. However, Viscoat®
can result in a mild transient rise in the intraocular
pressure.
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